Home › Compare › BCHHF vs ABBV
BCHHF yields 2.88% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, BCHHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BCHHF + ABBV for your $10,000?
Bucher Industries AG develops, manufactures, and sells machinery, vehicles, hydraulic components, and manufacturing equipment for use in harvesting, food producing and packaging, and roads and public spaces cleaning in Asia, the Americas, Europe, and internationally. The company operates through five divisions: Kuhn Group, Bucher Municipal, Bucher Hydraulics, Bucher Emhart Glass, and Bucher Specials. The Kuhn Group division manufactures and sells specialized agricultural machinery for tillage, planting and seeding, nutrient management and crop protection, hay and forage harvesting, and livestock bedding and feeding, as well as landscape maintenance. The Bucher Municipal division provides municipal vehicles, such as sweepers and sewer cleaning, winter maintenance, and refuse collection vehicles and equipment, as well as digital services. The Bucher Hydraulics division offers electronic and hydraulic components, such as pumps, motors, valves, cylinders, power units, power electronics, and system and manifold block solutions. The Bucher Emhart Glass division supplies manufacturing and inspection technologies for the glass container industry, as well as advice and support services. The Bucher Specials division offers equipment for wine, fruit juice, beer and instant products; and distributes tractors and specialized agricultural machineries, as well as provides automation solutions. The company is based in Niederweningen, Switzerland.
Full BCHHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.